Medical Oncologist
Your treatment timeline
How Long Does Trastuzumab — Take to Work?
Trastuzumab starts acting on HER2 receptors from your first infusion. But the question most people mean is: when will a scan show something? For most patients, the first formal assessment comes after two to three months of treatment.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Molecular from day one — The drug begins binding HER2 receptors from your first infusion, even before any visible change occurs on a scan.
- First scan usually at two to three months — Most oncologists schedule the first response assessment after three to four treatment cycles.
- Feeling unchanged is normal early on — No noticeable difference in the first few cycles does not mean the drug is not working.
- Timeline differs by setting — In early breast cancer treated before surgery, the clearest measure of response comes from the operation itself.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Trastuzumab begins acting on HER2 receptors from your first infusion, but meaningful response takes longer to establish. Most oncologists assess how well it is working after two to three months, using scans. In a proportion of patients receiving trastuzumab with chemotherapy, response becomes visible at that first assessment.
What is trastuzumab actually doing from your first infusion?
Trastuzumab is a monoclonal antibody — a protein engineered to seek out and bind to HER2, a receptor found in abnormally high numbers on some cancer cells. When HER2 is overactive, it drives rapid cell division. Trastuzumab blocks that signal.
It also marks cancer cells so your immune system can recognise and attack them. This dual action starts at a molecular level from the first dose, even when nothing visible has changed on a scan or in how you feel.
Tumour shrinkage is not the right thing to look for in the first cycle or two. What the treatment is doing in those early weeks is real but cannot yet be seen.
When is the earliest point that response is likely to show?
In the first three weeks — your first treatment cycle — nothing on a scan is expected to change. Feeling the same as you did before starting is entirely normal and is not a sign that the drug is failing.
Between weeks three and nine, some people notice that symptoms linked to the cancer begin to ease — pain from a lump, or breathlessness caused by fluid. This can be an early signal, but it is not a reliable measure of response on its own.
The first formal imaging assessment is usually scheduled after two to three months, corresponding to three or four treatment cycles. This is the earliest point at which most oncologists expect measurable evidence of whether the treatment is working.
If you are receiving trastuzumab before surgery for early HER2-positive breast cancer, the clearest measure of response comes at the time of the operation itself. The pathologist examines the removed tissue and looks for whether any cancer cells remain.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Questions people ask about the trastuzumab timeline
What if I feel no different after my first few infusions?
That is the expected experience for most people. Trastuzumab works at a cellular level, and the changes it causes in the first weeks are not the kind you can feel. Absence of noticeable symptoms does not mean the drug is failing. The formal answer to whether it is working comes from imaging, not from how you feel day to day. If you are concerned, the most useful step is to ask your oncologist when the first scan is scheduled — not to assume the treatment is ineffective.
How will my oncologist know whether it is working?
Response is assessed through imaging — usually a CT scan, and in some cases a PET-CT — combined with clinical examination. Your oncologist will compare the size of target lesions before and after treatment. In some situations, tumour markers in the blood are also monitored, though these are a supporting measure rather than the primary one. For early breast cancer treated before surgery, the pathology report after the operation is the definitive measure: it confirms whether cancer cells have been eliminated from the breast and lymph nodes.
What happens if the first scan shows no change?
Stable disease — where the cancer has neither grown nor shrunk — is a meaningful outcome, particularly in metastatic breast cancer. It means the treatment is holding the disease in place. Your oncologist will weigh that result against the risks and side effects of continuing. If there is clear progression — the cancer has grown despite treatment — they will discuss whether to add, change, or switch the regimen. An unchanged first scan is not automatically a reason to stop.
Does having side effects mean the drug is working?
No — side effects and treatment response are separate things. People who tolerate trastuzumab very well can have excellent responses, and people with noticeable side effects may not respond as well. The two are not linked. The most important side effect to monitor over time is its potential effect on the heart. Your oncology team checks cardiac function through regular heart scans throughout your treatment, not just when you notice something.
How does the timeline differ if trastuzumab is given with chemotherapy?
Most people receive trastuzumab alongside chemotherapy rather than alone. According to guidance from ASCO and NCCN, the combination generally produces a stronger response than either treatment by itself. The timing of the first formal assessment is similar — usually after two to three months — but in a neoadjuvant setting, where treatment is given before surgery, the goal is to reach what is called a pathological complete response by the time of the operation. Your oncologist will set the specific schedule based on your regimen and how your body is responding.
Did you know?
HER2-positive breast cancer was once considered one of the most aggressive subtypes of the disease. Trastuzumab was the first targeted therapy approved specifically for HER2-positive breast cancer, and its development fundamentally changed how oncologists classify and treat this group.
Knowing your HER2 status is not just a label — it is what makes trastuzumab a relevant treatment for you specifically.
Source: ASCO — History of HER2-Targeted Therapy in Breast Cancer
Explore 75 more Breast Cancer Targeted Medicines topics
Drug Deep Dive: Trastuzumab (Herceptin)
- Adjuvant Trastuzumab: Why Exactly 12 Months After Surgery?
- Diet and Nutrition While on Trastuzumab
- Drug, Food and Supplement Interactions With Trastuzumab
- Fatigue, Chills and Flu-Like Symptoms After a Trastuzumab Infusion
- Fertility, Pregnancy and Contraception on Trastuzumab
- Heart Function and Trastuzumab: Understanding Your ECHO Reports
- Herceptin vs Biosimilar Trastuzumab: Are They Really the Same?
- How Does Trastuzumab Work? The Anti-HER2 Monoclonal Antibody Explained
- How Long Does Trastuzumab Take to Work?
- How Long Will You Stay on Trastuzumab?
- Subcutaneous Trastuzumab vs IV Infusion: Which Suits You Better?
- Tests and Monitoring While You Are on Trastuzumab
- Trastuzumab (Herceptin and biosimilars): The Complete Patient Guide
- Trastuzumab Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Infusion Reactions: What Happens and How They're Managed
- Trastuzumab Myths: 'It's Chemotherapy' and Other Misunderstandings
- Trastuzumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Side Effects: The Complete List and Timeline
- Trastuzumab Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab With Pertuzumab, Chemotherapy and Hormone Therapy
- Trastuzumab in Elderly Patients and Those With Other Illnesses
- When Trastuzumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Trastuzumab? HER2-Positive Breast and Gastric Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab?
- Work, Travel and Daily Life on Trastuzumab
Drug Deep Dive: Palbociclib (Ibrance)
- Diet and Nutrition While on Palbociclib
- Drug, Food and Supplement Interactions With Palbociclib
- Fatigue on Palbociclib: Why It Happens and What Genuinely Helps
- Fertility, Pregnancy and Contraception on Palbociclib
- How Does Palbociclib Work? The CDK4/6 Inhibitor Explained
- How Long Does Palbociclib Take to Work?
- How Long Will You Stay on Palbociclib?
- Low White Cell Count on Palbociclib: Expected, and Rarely Dangerous
- Mouth Sores and Infection Risk on Palbociclib
- Palbociclib (Ibrance, Palbace): The Complete Patient Guide
- Palbociclib Myths: Low Counts, Hair Loss and Stopping Early
- Palbociclib Price in India: Brand, Generic and Monthly Cost
- Palbociclib Side Effects: The Complete List and Timeline
- Palbociclib Success Rate and Survival: An Honest Look at the Numbers
- Palbociclib With Letrozole or Fulvestrant: Understanding Your Combination
- Palbociclib in Early Breast Cancer: Why It Is Not Given After Surgery
- Palbociclib in Elderly Patients and Those With Other Illnesses
- Palbociclib vs Ribociclib vs Abemaciclib: Which CDK4/6 Inhibitor?
- Taking Palbociclib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Palbociclib
- The 21-Days-On, 7-Days-Off Palbociclib Cycle Explained
- When Palbociclib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Palbociclib? Hormone-Receptor-Positive, HER2-Negative Breast Cancer
- Will Insurance or a Government Scheme Pay for Palbociclib?
- Work, Travel and Daily Life on Palbociclib
Drug Deep Dive: Trastuzumab Deruxtecan (Enhertu)
- Diet and Nutrition While on Trastuzumab Deruxtecan
- Drug, Food and Supplement Interactions With Trastuzumab Deruxtecan
- Enhertu Myths: 'It's Just Stronger Herceptin' and Cost Misconceptions
- Enhertu in Breast, Gastric and Lung Cancer: One Drug, Three Diseases
- Fertility, Pregnancy and Contraception on Trastuzumab Deruxtecan
- HER2-Low Breast Cancer: How Enhertu Created an Entirely New Patient Group
- How Does Trastuzumab Deruxtecan Work? The HER2-Directed Antibody-Drug Conjugate Explained
- How Long Does Trastuzumab Deruxtecan Take to Work?
- How Long Will You Stay on Trastuzumab Deruxtecan?
- Interstitial Lung Disease on Enhertu: The Side Effect That Needs Immediate Action
- Low Blood Counts, Hair Loss and Heart Monitoring on Enhertu
- Nausea and Vomiting on Trastuzumab Deruxtecan: Managing a High-Risk ADC
- Tests and Monitoring While You Are on Trastuzumab Deruxtecan
- Trastuzumab Deruxtecan (Enhertu): The Complete Patient Guide
- Trastuzumab Deruxtecan Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Deruxtecan Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Deruxtecan Side Effects: The Complete List and Timeline
- Trastuzumab Deruxtecan Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab Deruxtecan in Elderly Patients and Those With Other Illnesses
- Trastuzumab Deruxtecan vs T-DM1 and Trastuzumab: How ADCs Differ
- When Trastuzumab Deruxtecan Stops Working: Resistance and What Comes Next
- Where Trastuzumab Deruxtecan Fits Alongside Chemotherapy and Hormone Therapy
- Who Is Eligible for Trastuzumab Deruxtecan? HER2-Positive and HER2-Low Breast, Gastric and Lung Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab Deruxtecan?
- Work, Travel and Daily Life on Trastuzumab Deruxtecan
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How many cycles of trastuzumab before you can tell if it is working?
Most oncologists schedule the first formal imaging assessment after three to four cycles, which corresponds to two to three months of treatment. Before that point, the drug is working at a molecular level but there is typically not enough visible change on a scan to draw a conclusion. Asking your team when the first scan is booked is a reasonable and useful question — you should know the date before you finish your first infusion.
Can you feel trastuzumab starting to work?
Some people notice that cancer-related symptoms — pain, swelling, or breathlessness caused by the disease — begin to ease within the first few weeks. This can be an early signal. But many people feel no different at all during the early cycles, and that is not a sign of failure. The only reliable measure of response is imaging, not how you feel from day to day.
How long is trastuzumab given in total?
According to NCCN guidelines, trastuzumab in early breast cancer is typically given for around one year in total, which spans the treatment period before and after surgery when relevant. In metastatic HER2-positive breast cancer, it is often continued for as long as the disease is responding and side effects remain manageable. Your oncologist will explain the planned duration at the start of your treatment.
What does pathological complete response mean?
Pathological complete response — often written as pCR — means that when the surgeon removes breast tissue and examines the lymph nodes, the pathologist finds no remaining cancer cells. It is the strongest measure of response to trastuzumab given before surgery. According to ASCO and NCCN guidance, achieving it is associated with a better outlook, though it is not the only measure of a good outcome. Your surgeon and oncologist will discuss what the pathology report shows after your operation.
What happens to the heart during trastuzumab treatment?
Trastuzumab can affect cardiac function in a proportion of patients, and this is monitored throughout your treatment with regular heart scans — usually an echocardiogram. Your oncology team will schedule these checks before treatment begins and at intervals during it. If a significant change in heart function is detected, treatment may be paused or adjusted. Most changes settle when treatment is interrupted, which is why monitoring is taken seriously from the start rather than waiting for symptoms.
Is trastuzumab available at CION?
Trastuzumab is administered as day care at CION centres across Telangana and Andhra Pradesh. If response assessment by PET-CT is part of your treatment plan, that is coordinated with partner imaging centres. Your oncologist at CION will set the schedule for infusions and assessments based on your individual plan.